About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Denosumab Treatment in CKD Patients at High Risk of Fracture

NCT05692297·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Dongliang Zhang, Director
CONTACT
+861058396938 zdlycy@163.com

Lead

Capital Medical University

Age

18–100

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

≥18 years old;
Stage 3b-5D chronic kidney disease;
The 10-year probability of hip fracture assessed by fracture risk assessment tool (FRAX) was \>5%;
Voluntarily signed informed consent.

You may not be if

Age \< 18 or ≥100 years;
Premenopausal women;
Denosumab was absolutely contraindicated;
Had received denosumab or bisphosphonates therapy;
Tertiary hyperparathyroidism;
Patients with malignant tumor;
Patients at risk for osteonecrosis of the jaw;
Estimated follow-up time ≤12 months.

The record

StatusUnknown

PhaseNo phase

Taking part102

StartedJan 2023

UpdatedJan 25, 2023

Conditions

Chronic Kidney Diseases Fracture Bone Density, Low End Stage Renal Disease

Where1

Nephrology Department of Beijing Jishuitan Hospital
Beijing, Beijing Municipality, China

Clareo Health | Denosumab Treatment in CKD Patients at High Risk of Fracture